Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well paclitaxel with and without nivolumab works in treating
patients with soft tissue sarcoma that have not received taxane drugs, and how well nivolumab
and cabozantinib work in treating taxane pretreated patients with soft tissue sarcoma.
Nivolumab works through the body's immune system to help the immune system act against tumor
cells. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. Cabozantinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. This trial is being done to see if the combination of
nivolumab and paclitaxel or cabozantinib can shrink soft tissue sarcoma and possibly prevent
it from coming back.